Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation

Angelos D. Karagiannis, Martin Liu, Peter P. Toth, Shijia Zhao, Devendra K. Agrawal, Peter Libby, Yiannis S. Chatzizisis

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of Review: Clinical trials with PCSK9 inhibitors have shown a robust decrease in plasma LDL levels and a significant reduction in the incidence of cardiovascular atherosclerotic events. However, the role of PCSK9 in atherosclerosis is not well investigated and it remains unclear whether PCSK9 inhibition has direct, LDL-independent, anti-atherosclerotic effects. This review outlines the molecular pathways and targets of PCSK9 in atherosclerosis and summarizes the experimental and clinical data supporting the anti-atherosclerotic (pleiotropic) actions of PCSK9 inhibitors. Recent Findings: PCSK9 is expressed by various cell types that are involved in atherosclerosis (e.g., endothelial cell, smooth muscle cell, and macrophage) and is detected inside human atherosclerotic plaque. Preclinical studies have shown that inhibition of PCSK9 can attenuate atherogenesis and plaque inflammation. Summary: Besides increasing plasma LDL, PCSK9 appears to promote the initiation and progression of atherosclerosis. Inhibition of PCSK9 may confer atheroprotection that extends beyond its lipid-lowering effects.

Original languageEnglish (US)
Article number20
JournalCurrent Atherosclerosis Reports
Volume20
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Molecular Biology
Atherosclerosis
Atherosclerotic Plaques
Smooth Muscle Myocytes
Endothelial Cells
Macrophages
Clinical Trials
Inflammation
Lipids
Incidence
oxidized low density lipoprotein

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation. / Karagiannis, Angelos D.; Liu, Martin; Toth, Peter P.; Zhao, Shijia; Agrawal, Devendra K.; Libby, Peter; Chatzizisis, Yiannis S.

In: Current Atherosclerosis Reports, Vol. 20, No. 4, 20, 01.04.2018.

Research output: Contribution to journalReview article

Karagiannis, Angelos D. ; Liu, Martin ; Toth, Peter P. ; Zhao, Shijia ; Agrawal, Devendra K. ; Libby, Peter ; Chatzizisis, Yiannis S. / Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation. In: Current Atherosclerosis Reports. 2018 ; Vol. 20, No. 4.
@article{8f87a126229c45c6a70d7012b5c7dd73,
title = "Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation",
abstract = "Purpose of Review: Clinical trials with PCSK9 inhibitors have shown a robust decrease in plasma LDL levels and a significant reduction in the incidence of cardiovascular atherosclerotic events. However, the role of PCSK9 in atherosclerosis is not well investigated and it remains unclear whether PCSK9 inhibition has direct, LDL-independent, anti-atherosclerotic effects. This review outlines the molecular pathways and targets of PCSK9 in atherosclerosis and summarizes the experimental and clinical data supporting the anti-atherosclerotic (pleiotropic) actions of PCSK9 inhibitors. Recent Findings: PCSK9 is expressed by various cell types that are involved in atherosclerosis (e.g., endothelial cell, smooth muscle cell, and macrophage) and is detected inside human atherosclerotic plaque. Preclinical studies have shown that inhibition of PCSK9 can attenuate atherogenesis and plaque inflammation. Summary: Besides increasing plasma LDL, PCSK9 appears to promote the initiation and progression of atherosclerosis. Inhibition of PCSK9 may confer atheroprotection that extends beyond its lipid-lowering effects.",
author = "Karagiannis, {Angelos D.} and Martin Liu and Toth, {Peter P.} and Shijia Zhao and Agrawal, {Devendra K.} and Peter Libby and Chatzizisis, {Yiannis S.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s11883-018-0718-x",
language = "English (US)",
volume = "20",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation

AU - Karagiannis, Angelos D.

AU - Liu, Martin

AU - Toth, Peter P.

AU - Zhao, Shijia

AU - Agrawal, Devendra K.

AU - Libby, Peter

AU - Chatzizisis, Yiannis S.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Purpose of Review: Clinical trials with PCSK9 inhibitors have shown a robust decrease in plasma LDL levels and a significant reduction in the incidence of cardiovascular atherosclerotic events. However, the role of PCSK9 in atherosclerosis is not well investigated and it remains unclear whether PCSK9 inhibition has direct, LDL-independent, anti-atherosclerotic effects. This review outlines the molecular pathways and targets of PCSK9 in atherosclerosis and summarizes the experimental and clinical data supporting the anti-atherosclerotic (pleiotropic) actions of PCSK9 inhibitors. Recent Findings: PCSK9 is expressed by various cell types that are involved in atherosclerosis (e.g., endothelial cell, smooth muscle cell, and macrophage) and is detected inside human atherosclerotic plaque. Preclinical studies have shown that inhibition of PCSK9 can attenuate atherogenesis and plaque inflammation. Summary: Besides increasing plasma LDL, PCSK9 appears to promote the initiation and progression of atherosclerosis. Inhibition of PCSK9 may confer atheroprotection that extends beyond its lipid-lowering effects.

AB - Purpose of Review: Clinical trials with PCSK9 inhibitors have shown a robust decrease in plasma LDL levels and a significant reduction in the incidence of cardiovascular atherosclerotic events. However, the role of PCSK9 in atherosclerosis is not well investigated and it remains unclear whether PCSK9 inhibition has direct, LDL-independent, anti-atherosclerotic effects. This review outlines the molecular pathways and targets of PCSK9 in atherosclerosis and summarizes the experimental and clinical data supporting the anti-atherosclerotic (pleiotropic) actions of PCSK9 inhibitors. Recent Findings: PCSK9 is expressed by various cell types that are involved in atherosclerosis (e.g., endothelial cell, smooth muscle cell, and macrophage) and is detected inside human atherosclerotic plaque. Preclinical studies have shown that inhibition of PCSK9 can attenuate atherogenesis and plaque inflammation. Summary: Besides increasing plasma LDL, PCSK9 appears to promote the initiation and progression of atherosclerosis. Inhibition of PCSK9 may confer atheroprotection that extends beyond its lipid-lowering effects.

UR - http://www.scopus.com/inward/record.url?scp=85043495681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043495681&partnerID=8YFLogxK

U2 - 10.1007/s11883-018-0718-x

DO - 10.1007/s11883-018-0718-x

M3 - Review article

VL - 20

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 4

M1 - 20

ER -